- Home
- NODK vs LCTX Comparison
NODK vs LCTX Comparison
Compare NODK & LCTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NODK
- LCTX
- Stock Information
- Founded
- NODK 1946
- LCTX 1990
- Country
- NODK United States
- LCTX United States
- Employees
- NODK N/A
- LCTX N/A
- Industry
- NODK Property-Casualty Insurers
- LCTX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- NODK Finance
- LCTX Health Care
- Exchange
- NODK Nasdaq
- LCTX Nasdaq
- Market Cap
- NODK 277.0M
- LCTX 274.0M
- IPO Year
- NODK 2017
- LCTX N/A
- Fundamental
- Price
- NODK $14.01
- LCTX $1.56
- Analyst Decision
- NODK
- LCTX Strong Buy
- Analyst Count
- NODK 0
- LCTX 4
- Target Price
- NODK N/A
- LCTX $4.25
- AVG Volume (30 Days)
- NODK 10.8K
- LCTX 1.2M
- Earning Date
- NODK 11-06-2025
- LCTX 11-13-2025
- Dividend Yield
- NODK N/A
- LCTX N/A
- EPS Growth
- NODK N/A
- LCTX N/A
- EPS
- NODK 0.07
- LCTX N/A
- Revenue
- NODK $310,389,000.00
- LCTX $10,914,000.00
- Revenue This Year
- NODK N/A
- LCTX N/A
- Revenue Next Year
- NODK N/A
- LCTX $176.00
- P/E Ratio
- NODK $195.82
- LCTX N/A
- Revenue Growth
- NODK N/A
- LCTX 76.43
- 52 Week Low
- NODK $12.01
- LCTX $0.37
- 52 Week High
- NODK $17.24
- LCTX $1.42
- Technical
- Relative Strength Index (RSI)
- NODK 64.08
- LCTX 76.02
- Support Level
- NODK $13.13
- LCTX $1.20
- Resistance Level
- NODK $14.34
- LCTX $1.42
- Average True Range (ATR)
- NODK 0.30
- LCTX 0.08
- MACD
- NODK 0.07
- LCTX 0.02
- Stochastic Oscillator
- NODK 77.85
- LCTX 98.78
About NODK NI Holdings Inc.
NI Holdings Inc is a stockholding company. The company's operating segments include private passenger auto insurance, non-standard auto insurance, home and farm insurance, crop insurance, commercial insurance, and others. The company operates only in USA.
About LCTX Lineage Cell Therapeutics Inc.
Lineage Cell Therapeutics Inc is a clinical-stage biotechnology company focused on the development and commercialization of novel therapies for the treatment of degenerative diseases. The company's pipeline is based on two platform technologies including cell replacement and cell/drug delivery. Lineage Cell's product candidate is OpRegen, a retinal pigment epithelium transplant therapy for the treatment of dry age-related macular degeneration, OPC1, an oligodendrocyte progenitor cell therapy for acute spinal cord injuries, and VAC2, allogeneic cancer immunotherapy of antigen-presenting dendritic cells for non-small cell lung cancer, ANP1, an allogeneic auditory neuron progenitor cells transplant for hearing loss, and PNC1, an allogeneic photoreceptor cell transplant for vision loss.